Ignite Creation Date:
2024-05-06 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06248697
Status:
RECRUITING
Last Update Posted:
2024-02-08
First Post:
2024-01-31
Brief Title:
Exploratory Study of MSLN-CAR T Cells Secreting PD1CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
Sponsor:
Shanghai Cell Therapy Group CoLtd
Organization:
Shanghai Cell Therapy Group CoLtd
Study Overview
Official Title:
Exploratory Study of MSLN-CAR T Cells Secreting PD1CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single arm open-label dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin MSLN-targeted chimeric antigen receptor MSLN-CAR T cells secreting PD-1 and CTLA-4 nanobodies αPD1CTLA-4-MSLN-CAR T cells in patients with solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None